Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-… (NCT07235527) | Clinical Trial Compass
RecruitingNot Applicable
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
Turkey (Türkiye)54 participantsStarted 2025-11-20
Plain-language summary
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
Who can participate
Age range
45 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)
* who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)
* for whom intravitreal injection has already been clinically indicated
Exclusion Criteria:
* Patients younger than 45 years or older than 90 years
* History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months
* Presence of uveitis
* Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)
* Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)
* Presence of hereditary retinal dystrophies
* Presence of optic atrophy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Best-Corrected Visual Acuity (BCVA) and Central Macular Thickness After MY-1701P Injection